Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F24%3A10486104" target="_blank" >RIV/00179906:_____/24:10486104 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/24:10486104
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=elDp15TywK" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=elDp15TywK</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.lanepe.2024.100839" target="_blank" >10.1016/j.lanepe.2024.100839</a>
Alternative languages
Result language
angličtina
Original language name
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
Original language description
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Regional Health. Europe
ISSN
2666-7762
e-ISSN
2666-7762
Volume of the periodical
38
Issue of the periodical within the volume
MAR
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
100839
UT code for WoS article
001205663600001
EID of the result in the Scopus database
2-s2.0-85186523281